No Data
Zhejiang Yatai Pharmaceutical (002370.SZ): Received the approval notification for the supplementary application of injectable Cefoperazone Sodium Pharmaceutical.
On December 13, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received the "Notification of Approval for Supplemental Application of Pharmaceuticals" issued by the National Medical Products Administration for injectable cefmetazole sodium. Cefmetazole sodium is highly stable against β-lactamase and has strong antibacterial activity against both β-lactamase-producing and non-producing sensitive bacteria. It has good antibacterial effects against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, and is also effective against common Proteus species that are resistant to cephalosporins and penicillin antibiotics.
Zhejiang Yatai Pharmaceutical (002370.SZ): Termination of the funding project for Convertible Bonds.
On December 11, Ge Long Hui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that at the 33rd meeting of the 7th Board of Directors and the 18th meeting of the 7th Supervisory Board held on December 11, 2024, it approved the "Proposal for Terminating the Fundraising Project for Convertible Bonds." 1. The Phase I and II projects of Zhejiang Yatai Pharmaceutical Modern Pharmaceutical Formulations consist of two independent lyophilized powder injection workshops, a penicillin workshop, a solid preparations workshop, a cephalosporin workshop (capsules and powder injections), a patch workshop, a raw and auxiliary materials finished product warehouse, a quality inspection workshop, a Sewerage treatment center, and dormitories.
Zhejiang Yatai Pharmaceutical (002370.SZ): Injectable Pantoprazole Sodium passed the consistency evaluation.
Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received approval and issuance of the State Food and Drug Administration regarding...
Zhejiang Yatai Pharmaceutical's Diltiazem Hydrochloride Tablets Enter Consistency Evaluation Review Stage
Asia Pacific Pharmaceutical: Report for the third quarter of 2024
zhejiang yatai pharmaceutical (002370.SZ): a net loss of 3.4595 million yuan in the first three quarters.
Gelonghui On October 30th, Zhejiang Yatai Pharmaceutical (002370.SZ) released its third-quarter report for 2024, achieving revenue of 0.307 billion yuan in the first three quarters, a year-on-year increase of 1.65%; net income attributable to the shareholders of the listed company was -3.4595 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -22.5921 million yuan; basic earnings per share was -0.0056 yuan.
Some Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) Shareholders Look For Exit As Shares Take 26% Pounding
